VGX-100 is a human antibody that acts against the human VEGF-C protein and is indicated in the treatment for cancers, particularly glioblastoma and metastatic colorectal cancers.
The company is developing VGX-100 for a number of other cancer indications, as well as an agent to treat front-of the-eye diseases.
The trial is intended to evaluate the safety and tolerability of escalating doses of VGX-100 in patients with advanced solid tumours who have no other standard treatment options both as a monotherapy and also when used in combination with other anti-angiogenic agents.
Circadian CEO Robert Klupacs said the company has completed the translation of VGX-100 from early discovery to the clinical development stage.
"Commencing clinical trials with VGX-100 is an extremely important achievement for Circadian and a major step in our goal to develop VGX-100 as a new therapeutic agent in the fight against cancer," Klupacs added.
The company is likely to announce the results in the second half of 2012.